Eli Lilly LLY and Merck MRK are leading global pharmaceutical companies with blockbuster drug portfolios and promising pipelines. Both have a strong presence in oncology, immunology and neuroscience. Lilly has established a leadership position in cardiometabolic health, with its GLP-1 drugs Mounjaro and Zepbound contributing around 65% of total revenues. Merck, meanwhile, relies heavily on oncology, with its blockbuster cancer drug Keytruda accounting for around 55% of pharmaceutical sales. Which stock offers a more attractive investment opportunity today? A comparison of their fundamentals, growth prospects and key challenges can help investors assess their relative appeal.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.